ETC-1002
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Safety Evaluation of Escalating Doses
Conditions
Safety Evaluation of Escalating Doses
Trial Timeline
Oct 25, 2011 → Jan 25, 2012
NCT ID
NCT01485146About ETC-1002
ETC-1002 is a phase 1 stage product being developed by Esperion Therapeutics for Safety Evaluation of Escalating Doses. The current trial status is completed. This product is registered under clinical trial identifier NCT01485146. Target conditions include Safety Evaluation of Escalating Doses.
What happened to similar drugs?
3 of 4 similar drugs in Safety Evaluation of Escalating Doses were approved
Approved (3) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
6
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01485146 | Phase 1 | Completed |
Competing Products
20 competing products in Safety Evaluation of Escalating Doses